Trilobio Unveils Revolutionary Whole-Lab Automation Platform at SLAS2025: A Game-Changer for Life Science Research San Diego, CA – January 25-29, 2025 – Trilobio, a pioneering developer of whole-laboratory automation solutions,…
Sage Therapeutics Explores Strategic Alternatives and Rejects Biogen’s Acquisition Offer Sage Therapeutics, Inc. (Nasdaq: SAGE), a leader in brain health therapeutics, announced today that its Board of Directors has initiated…
Inventia Life Science Unveils RASTRUM™ Allegro to Transform 3D Cell Culture in Drug Discovery and Disease Research Inventia Life Science, a leader in 3D cell culture technologies, has announced the…
Genentech Announces Positive OS Results for Itovebi in Advanced HR-Positive Breast Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive topline results from…
Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth,…
ENHERTU® Approved in U.S. for HER2-Low Metastatic Breast Cancer Post-Endocrine Therapy Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment…
Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, has officially launched the Ncyte® Heart in a Box, an innovative 3D model of cardiac microtissue designed to…
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D., as Chief Medical Officer Arcus Bioscience a clinical-stage biopharmaceutical Officer company focused on developing novel molecules and combination therapies for cancer treatment, has…
Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising…
Roche Receives FDA Clearance for CLIA-Waived STI Point-of-Care Tests Roche has announced a major milestone in the realm of sexual health diagnostics. The U.S. Food and Drug Administration (FDA) has…
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of…
Introduction: Cytokinetics Advances CK-586 into Phase 2 Trial Cytokinetics, Incorporated a leading biopharmaceutical company, has announced that enrollment is now open for AMBER-HFpEF, a pivotal Phase 2 clinical trial evaluating…
